Business Wire

ADVA and PSNC showcase 1200G channel transmission at SC19

Share

ADVA (FSE: ADV) today announced that it’s hosting a joint showcase with PSNC at SC19 that features the industry’s first 1200Gbit/s optical channel transmission. Built upon the ADVA FSP 3000 TeraFlex™ terminal, the demo underscores the power of adaptive technology to maximize bandwidth efficiency in any network scenario. Using fractional QAM capabilities to boost fiber utilization and channel capacity, the demo highlights how network operators and enterprises can cost-effectively inject capacity into their networks without major upgrades. At SC19, TeraFlex™ will carry 1200Gbit/s channels in a 150GHz window or 800Gbit/s channels in a 100GHz window, delivering an industry-leading spectral efficiency of 8bit/s/Hz. These figures set a new benchmark for a commercially available product. The ADVA FSP 3000 TeraFlex™ has now been shipping for several months.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191119005670/en/

The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)

The FSP 3000 TeraFlex™ helps customers inject capacity into their networks without major upgrades (Photo: Business Wire)

“As we approach the Shannon Limit, our compact and open FSP 3000 TeraFlex™ provides an entirely new route to network capacity expansion. This demo reveals how operators can enhance optical paths and reduce cost per bit right now,” said Christoph Glingener, CTO, ADVA. “Transmission terminal design is all about utilizing fiber in the most efficient way, and that’s why our FSP 3000 TeraFlex™ is the high-speed terminal of choice. By providing a 1200Gbit/s channel that consumes only 150GHz of spectrum, we’re leading the industry with spectral efficiency and channel capacity. Compared with the promise of rival 800Gbit/s solutions that are still many months away, we’re delivering 50% more capacity today – and with the added bonus of significantly better reach.”

Presented at SC19, the live demo highlights how spectral efficiency is key to maximizing bandwidth in existing networks. It shows how super-channels in increments of 50GHz are ideal for maximizing client port flexibility while ensuring compatibility with legacy line systems. Using software-defined fractional QAM modulation and adaptive baud rate capabilities, the ADVA FSP 3000 TeraFlex™ can support 1200Gbit/s channels carrying three 400Gbit/s clients or 800Gbit/s channels carrying two 400Gbit/s clients. The reach and spectral efficiency of the dual-core coherent engine implementation is superior to future single-core 800Gbit/s concepts that have reduced client port flexibility and often leave spectrum unutilized.

“Terabit channels are fast becoming essential. Our network enables Europe’s scientific community to share huge data sets and access the most advanced supercomputing applications. But empowering those researchers to stay at the forefront of discovery requires a new level of reach and spectral efficiency. With this demo, we’re showing how mission-critical long-haul networks like ours, which are not fiber-rich, can meet unprecedented data demand,” commented Artur Binczewski, director, Network Division, PSNC. “The ADVA FSP 3000 TeraFlex™ provides the flexibility and granularity needed to squeeze maximum value from our fiber plant. Now we can transmit twelve 100Gbit/s or three 400Gbit/s signals in a single Terabit channel that consumes just 150GHz of spectrum. That level of efficiency enables us to achieve more than we ever thought possible with our DCI network.”

The demo will be on display at SC19 at booth 1955 until Thursday, November 21.

Further details of the demo are available in these slides: https://adva.li/sc19-slides.


About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we're building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About PSNC
Poznan Supercomputing and Networking Center (PSNC) affiliated to the Institute of Bioorganic Chemistry of the Polish Academy of Sciences is an internationally known node of the European Research Area in the field of IT infrastructure of science and an important R&D center in the field of information and communication technologies (ICT). As a development center of e-Infrastructure, PSNC designed and built the Metropolitan Network POZMAN, High Performance Computing Center and the national broadband network PIONIER, maintained and still developed by PSNC. We are an institution of high development potential. A positive consequence of the Centre's exemplary activity in acquiring and implementing projects was the establishment of broad cooperation with international institutions. Projects developed at PSNC include cooperation with 927 units from 59 countries. All projects are focused on IT technology and concern new generation networks, grids, portals, digital libraries, IT energy efficiency, climate, weather, air quality, new sources of energy, digital humanities, personalized medicine, intelligent agriculture, industry 4.0, astronomy, bioinformatics, Big Data analysis, artificial intelligence, New Media, education, Smart City, cyber security. The list of areas of activity in which PSNC undertakes work is constantly expanding, providing an important example of taking up new technological challenges. www.man.poznan.pl/online/en

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EETPress release

Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a

Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma

Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EETPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu

Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu

Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EETPress release

Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer

BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EETPress release

BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom